| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income, net | 147 | 153 | 42 | 155 |
| Net loss | -7,448 | -8,482 | -12,257 | -8,660 |
| Unrealized gain from available-for-sale securities | 1 | - | - | - |
| Comprehensive loss | -7,447 | -8,482 | -12,257 | -8,660 |
| Net loss per common share, basic | -0.07 | -0.09 | -0.17 | -0.17 |
| Net loss per common share, diluted | -0.07 | -0.09 | -0.17 | -0.17 |
| Weighted average common shares outstanding, basic | 100,869,349 | 95,459,401 | 74,254,700 | 51,229,701 |
| Weighted average common shares outstanding, diluted | 100,869,349 | 95,459,401 | 74,254,700 | 51,229,701 |
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)